We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

42 hedge funds and large institutions have $61.5M invested in Ovid Therapeutics in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 11

3.13% less ownership

Funds ownership: 32.49% → 29.36% (-3.1%)

7% less funds holding

Funds holding: 45 → 42 (-3)

25% less capital invested

Capital invested by funds: $81.8M → $61.5M (-$20.3M)

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

Holders
42
Holders Change
-3
Holders Change %
-6.67%
% of All Funds
1.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
12
Reduced
11
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$519K
2
DCM
Driehaus Capital Management
Illinois
+$392K
3
State Street
State Street
Massachusetts
+$186K
4
Jennison Associates
Jennison Associates
New York
+$145K
5
CI
Cowen Inc
New York
+$85K

Top Sellers

Rank Fund Capital Flow
1
TCM
Tekla Capital Management
Massachusetts
-$3.11M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.41M
3
Goldman Sachs
Goldman Sachs
New York
-$923K
4
Ameriprise
Ameriprise
Minnesota
-$489K
5
LOAMU
Lombard Odier Asset Management (USA)
New York
-$328K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$13.8M -$1.41M -169,802 -9%
BlackRock
2
BlackRock
New York
$9.34M -$258K -30,958 -3%
Jennison Associates
3
Jennison Associates
New York
$5.86M +$145K +17,392 +3%
RG
4
Redmile Group
California
$3.77M +$20K +2,401 +0.5%
O
5
OppenheimerFunds
New York
$3.64M -$2.33K -280 -0.1%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$2.97M – – –
BBA
7
Baker Bros. Advisors
New York
$2.86M – – –
SFM
8
Sphera Funds Management
Israel
$2.62M – – –
Ameriprise
9
Ameriprise
Minnesota
$2.57M -$489K -58,691 -16%
DCM
10
Driehaus Capital Management
Illinois
$2.27M +$392K +47,056 +22%
CAM
11
Cormorant Asset Management
Massachusetts
$1.92M – – –
CC
12
Casdin Capital
New York
$1.78M -$118K -14,200 -6%
Deutsche Bank
13
Deutsche Bank
Germany
$1.75M -$11.1K -1,332 -0.6%
TCM
14
Tekla Capital Management
Massachusetts
$1.39M -$3.11M -373,287 -70%
Vanguard Group
15
Vanguard Group
Pennsylvania
$1.39M +$519K +62,340 +63%
Victory Capital Management
16
Victory Capital Management
Texas
$866K -$250K -29,970 -23%
State Street
17
State Street
Massachusetts
$616K +$186K +22,335 +45%
Northern Trust
18
Northern Trust
Illinois
$493K – – –
Geode Capital Management
19
Geode Capital Management
Massachusetts
$290K +$50.4K +6,057 +22%
SSA
20
Schonfeld Strategic Advisors
New York
$287K -$12.5K -1,500 -4%
AA
21
ALPS Advisors
Colorado
$208K +$16.8K +2,023 +9%
TCIM
22
TIAA CREF Investment Management
New York
$126K +$9.43K +1,132 +8%
Charles Schwab
23
Charles Schwab
California
$125K – – –
Bank of New York Mellon
24
Bank of New York Mellon
New York
$110K -$266 -32 -0.2%
CI
25
Cowen Inc
New York
$88K +$85K +10,211 New
1
2 3

OVID Hedge Fund Activity: Q3 2017 in Review

42 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q3 2017, worth a combined $61.5M — down 25% from $81.8M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of OVID and 6 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 12 added.

The largest buyer was Vanguard Group, adding an estimated $519K. The largest seller was Tekla Capital Management, cutting an estimated $3.11M.

  • 42 institutional investors held Ovid Therapeutics (OVID) as of Q3 2017, down from 45 in Q2 2017.
  • Funds reported $61.5M of Ovid Therapeutics stock for Q3 2017, down 25% quarter-over-quarter.
  • 6 funds opened new Ovid Therapeutics positions in Q3 2017 and 9 closed out, a net change of -3 holders.
  • The largest Ovid Therapeutics buyer in Q3 2017 was Vanguard Group, an estimated $519K added.
  • The largest Ovid Therapeutics seller in Q3 2017 was Tekla Capital Management, an estimated $3.11M sold.

Based on aggregated 13F filings for Q3 2017.